摘要
目的研究黄芪注射液(HQI)对大鼠实验性肾病模型的治疗作用。方法采用静脉注射阿霉素制造大鼠实验性肾病模型。静脉注射阿霉素2周后,开始治疗性腹腔注射给药42d,黄芪注射液低、高剂量组分别腹腔注射HQI2g/kg和10g/kg,每日用药1次。模型对照组每日腹腔注射无菌生理盐水每只0.5ml/d。结果模型对照组的病死率为53%(8/15)。HQI治疗组的一般状态较好,HQI高剂量组大鼠的病死率为27%(4/15)。静脉注射阿霉素8周末,模型组大鼠血清总蛋白和白蛋白显著下降,血清肌酐含量显著升高,血清总胆固醇显著升高。与模型对照组比较,HQI治疗组的血清总蛋白和白蛋白显著升高;血清总胆固醇和血清肌酐显著降低。与生理对照组比较,模型对照组的血脂显著增高,血液黏度增高,而HQI治疗组无显著性改变。病理检查表明HQI治疗组肾组织损伤明显减轻。结论HQI对大鼠实验性肾病有显著的治疗作用。
Objective The therapeutic effects of astragalus injection (HQI) on adriamycin-induced nephropathy rats were studied. Methods Two weeks after intravenous injection (iv) adriamycin, the therapeutic program began. The rats in HQI-treated groups received intraperitoneal injection (ip) of HQI 2 or 10 g/kg, once a day. The therapeutic course was 42 days. Results The mortality rate of the model group and that of HQI high dose group was 8/15 and 4/15 respectively. At the end of 8 week after iv adriamycin, serum total protein and albumin levels in the model group were significantly reduced. Whereas, serum creatinine and total cholesterol were remarkably elevated, compared with the saline group. Compared with the model group, serum total protein and albumin were significantly higher; serum total cholesterol and creatinine were significantly lowered. Hemorheologic measurements indicated blood viscidity in the model group, but not in HQI-treated group, was significantly higher than the saline group. Histologic findings suggested that the lesion in the HQI-treated group was slighter than in the model group. Conclusion Astragalus injection (HQI) has a remarkable effect on adriamycin-induced nephropathy in rats.
出处
《中国药物与临床》
CAS
2004年第10期771-773,共3页
Chinese Remedies & Clinics